Analyzing CNS Pharmaceuticals (NASDAQ:CNSP) & KalVista Pharmaceuticals (NASDAQ:KALV)

CNS Pharmaceuticals (NASDAQ:CNSP) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Valuation and Earnings

This table compares CNS Pharmaceuticals and KalVista Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$18.85 million	($3,748.50)	0.00
KalVista Pharmaceuticals	N/A	N/A	-$126.64 million	($3.72)	-2.77

KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CNS Pharmaceuticals and KalVista Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	N/A	-515.32%
KalVista Pharmaceuticals	N/A	-103.92%	-88.06%

Insider and Institutional Ownership

14.0% of CNS Pharmaceuticals shares are held by institutional investors. 0.1% of CNS Pharmaceuticals shares are held by insiders. Comparatively, 10.5% of KalVista Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

CNS Pharmaceuticals has a beta of 2.72, meaning that its stock price is 172% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for CNS Pharmaceuticals and KalVista Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	0	1	0	1	3.00
KalVista Pharmaceuticals	0	0	7	1	3.13

CNS Pharmaceuticals currently has a consensus target price of $25.00, indicating a potential upside of 2,327.18%. KalVista Pharmaceuticals has a consensus target price of $24.83, indicating a potential upside of 140.63%. Given CNS Pharmaceuticals’ higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than KalVista Pharmaceuticals.

Summary

CNS Pharmaceuticals beats KalVista Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.